Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BPH (Benign Prostatic Hyperplasia) Clear all
Completed Phase 3 Interventional Results available

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

NCT00090103
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
4,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
113
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jun 10, 2026, 2:07 AM EDT
Withdrawn Not applicable Interventional

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

NCT02679430
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Arterial Embolization
Device
Lead sponsor
Antonios Likourezos
Other
Eligibility
35 Years to 99 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting No phase listed Observational

Customized TULSA-PRO Ablation Registry

NCT05001477
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Interventions
TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2061
U.S. locations
5
States / cities
West Hills, California • Jacksonville, Florida • York, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jun 10, 2026, 2:07 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

ProVIDE II Bridging Study

NCT06236802
View directory record Official record
Conditions
BPH With Symptomatic Lower Urinary Tract Symptoms
Interventions
ProVee device
Device
Lead sponsor
ProVerum Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
7
States / cities
Tampa, Florida • Winter Garden, Florida • Lake Barrington, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02026908
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT01107392
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin Type A, Normal saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting No phase listed Observational

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

NCT06560476
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Data collection
Other
Lead sponsor
Urotronic Inc.
Industry
Eligibility
Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Kearney, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

NCT03123250
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Aquablation
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

NCT00939120
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Tolterodine ER 4mg, Placebo, Pre-randomization Dutasteride
Drug
Lead sponsor
Siami, Paul F., M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newburgh, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jun 10, 2026, 2:07 AM EDT
Withdrawn Early Phase 1 Interventional

Ga-68 MAA Distribution in PAE Patients

NCT04243824
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Gallium 68 Macro-aggregated albumin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ejaculatory-Sparing HoLEP vs Standard HoLEP

NCT07631286
View directory record Official record
Conditions
Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Ejaculatory-sparing (ES-sparing) HoLEP
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 2:07 AM EDT
Terminated Phase 3 Interventional Results available

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00449150
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
46
States / cities
Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Phase 3 Interventional

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

NCT00945490
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
NX-1207, Placebo
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
35
States / cities
Laguna Hills, California • San Diego, California • Tarzana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting No phase listed Observational

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

NCT03354416
View directory record Official record
Conditions
Prostatic Cancer, Prostatic Neoplams, Prostatic Hyperplasia, Prostate Cancer, Cancer Of Prostate
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT04757116
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
iTind, UroLift
Device · Procedure
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT03055624
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Embosphere microparticles for prostate artery embolization
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jun 10, 2026, 2:07 AM EDT
Withdrawn Not applicable Interventional

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT04563221
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Prostatic artery embolization
Device
Lead sponsor
Andrew Picel
Other
Eligibility
45 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960
View directory record Official record
Conditions
Nocturia
Interventions
Fedovapagon 2 mg, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jun 10, 2026, 2:07 AM EDT
Recruiting No phase listed Observational

Effect of Group Preoperative Pelvic Floor Training for HoLEP

NCT05719220
View directory record Official record
Conditions
BPH, Urinary Incontinence
Interventions
Group preoperative pelvic floor training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 90 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jun 10, 2026, 2:07 AM EDT
Not listed Not applicable Interventional

Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)

NCT00274417
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
dutasteride
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
50 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Norfolk, Virginia • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Jun 10, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial

NCT04263987
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Moses laser enucleation of prostate
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 90 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 10, 2026, 2:07 AM EDT
Completed No phase listed Observational Results available

Real World Data on Management of Male LUTS

NCT03075449
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jun 10, 2026, 2:07 AM EDT